R&D expenditures for the one fourth ended December 31, 2012 totaled $2,924,722 versus R&D expenditures of $2,456,185 for the one fourth ended December 31, 2011. R&D expenses increased due to the increased degree of activity connected with conducting the Company's Stage III clinical study. The Company ended the December quarter with approximately $10,736,000 in cash and cash equivalents. Through the quarter, the business completed a Registered Direct financing, producing net proceeds of $9,807,000. Geert Kersten, CEO said, We continue to make significant progress inside our pivotal global Phase III scientific trial of Multikine .Volume pricing can be available. Herceptin is one of a new era of targeted therapies which assault only cancers cells and are tolerated superior to traditional chemotherapy. The medication is already used for advanced cancers and other women in the same scenario as 54 year previous Ms Rogers have been given the medication. Campaigners are actually calling for clearness on who should have access to the medication. The conflict of views has risen as the drug is yet to be licensed or authorized by medical authorities for use in females with early stage breasts cancer, meaning your choice over who gets the drug is left to specific major care trusts.